SABCS 2025

A milestone for ET in HR+ HER2- and important follow-up…

Firstline treatment of MBC: Which strategy is best?

Patients contribution is essential

PALLAS trial and ctDNA

Revolution in adjuvant endocrine therapy?

Therapy optimization: Endocrine approaches in…

ALTTO trial outcome according to endocrine therapy

Giredestrant will replace current adjuvant therapy

SERDs now in adjuvant therapy

Surgery remains soc in low risk EBC

SERDs in early breast cancer - the new era has begun?

ctDNA analysis could optimize the approach in HER2+

Optimized endocrine therapy for premenopausal patients

Significant innovations in early and metastatic HER2+…

Safety data DB11

Quality of live data DB11

Platinum adjuvant in TNBC

In addition to pCR, ctDNA is prognostically relevant…

Carboplatin in adjuvant setting of TNBC

Otimização da terapia: abordagens endócrinas em…

Carboplatino nel contesto adiuvante del TNBC

Risultati dello studio ALTTO in base alla terapia…

SERDy we wczesnym raku piersi -początek nowej epoki?

La chirurgia rimane lo standard di cura nei casi di…

Triple-positive MBC: less chemotherapy, more endocrine…

Chemotherapy-free treatment: a promising therapeutic…

Elacestrant is a good combination partner for HR+ HER2+…

Updated results of VIKTORIA-1

The significance of SG is more clearly defined

Palbociclib likely delays CNS progression

Phase 2 combination of elacestrant with everolimus or…

No improvement over standard therapy

Traditional chemotherapy should not be forgotten as…

Elacestrant as oral endocrine backbone

Biomarker and clinical subgroup analysis of evERA…

ASCENT-07 a negative trial

Significant innovations in early and metastatic HER2+…

CDK4/6 inhibitor + endocrine therapy remains the…

Tucatinib a new SERD in the adjuvant setting

Monitoring of ILD

New evidence for oral SERDs

Maintenance therapy HER2+ Tucatinib as a new option

Tucatinib, un nouveau SERD dans le cadre d'un…

Jeszcze nie czas na rezygnację z tradycyjnej…

Sem melhorias em relação à terapia padrão

Résultats actualisés de VIKTORIA-1

Nuove prove a favore dei SERD orali

Risultati aggiornati di VIKTORIA-1

Elacestrant come partner endocrino orale